Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases
Anti-CD45 (YTH-24 & YTH 54) and ANTI-CD52 (CAMPATH-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases
Sponsor: Baylor College of Medicine
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Baylor College of Medicine
This PHASE1/PHASE2 trial investigates Inherited Metabolic Storage Diseases and is currently terminated or withdrawn. Baylor College of Medicine leads this study, which shows 8 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Feb 2020 [monthly]
Terminated PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1_PHASE2
First recorded
Jun 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
- The Methodist Hospital Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .